Implantation or Injectable Dosage Form New Animal Drugs; Lufenuron Suspension

Özet

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for subcutaneous use of lufenuron suspension in cats for control of flea populations.